Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 13, 2026 RaQualia Pharma Inc. [4579.T] TOKYO, Feb 13 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) announced resignations from its executive leadership effective February 13, 2026. * Key changes: * Representative Director: 代表者名 代表取締役 須 藤 正樹 * Executive Officer: 問合せ先 執行役員経営管理部門担当 志 水 幹憲 * Director: 当社は、本日開催の取締役会において、下記のとおり役員の異動について決議いたしましたので、お知 * Director: １． 取締役の異動 * Director: （１）新任取締役候補者 * Director: 宋 根石 社外取締役 ― * Director: 棚瀬 敦 社外取締役 ―
Source disclosure: February 13, 2026
RaQualia Pharma Inc. [4579.T]
TOKYO, Feb 13 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) announced resignations from its executive leadership effective February 13, 2026.
AI-translated content. 🔴 Confidence: Review recommended See terms • Original filing